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Abstract
Visual symptoms often accompany pituitary diseases. Pituitary tumors may compress 
surrounding structures such as optic chiasm leading to visual field defects including 
bitemporal hemianopia and visual disturbance. They also may compress cranial nerves 
III, IV, and VI, leading to ocular motility abnormalities. Pituitary adenomas are the most 
common cause of chiasmal compression. Patients with nonsecreting tumors present 
initially with vision loss, and these tumors can reach large size without causing other 
symptoms; however, hormonally active tumors are detected before vision loss because 
of systemic symptoms. Acute hemorrhage or infarction of the pituitary tumor known as 
pituitary apoplexy causes diplopia, loss of vision, and visual field. Thus, the ophthal-
mologist’s role is crucial in diagnosis and treatment of pituitary tumors. As visual loss 
may be the first sign of recurrence after treatment, it is essential to repeat visual field and 
visual acuity testing every 6–12 months.
Keywords: pituitary tumors, pituitary adenoma, pituitary apoplexy, 
chiasmal compression, bitemporal hemianopia, ocular motility abnormalities, 
craniopharyngioma, suprasellar meningioma, parasellar meningioma
1. Introduction
Pituitary diseases are the most common causes of extrinsic compressive chiasmal syndromes 
leading to visual disturbances. Chiasmal syndromes most commonly occur secondary to pitu-
itary adenomas, craniopharyngiomas, meningiomas, and pituitary apoplexy.
Visual field defects may be one of the first signs of nonfunctional pituitary tumors growing in 
the vertical direction [1]. Visual disturbances are much less frequent in functional adenomas, 
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where systemic hormonal aberrations such as Cushing’s syndrome, galactorrhea, and acro-
megaly usually predate the compressive signs [2].
However, pituitary tumors may grow in the horizontal direction to invade the cavernous sinus. 
This will cause dysfunction of cranial nerves III, IV, V, and VI, with less visual damage [1].
2. Anatomy
2.1. Optic nerve
The optic nerve extends from the retina to the optic chiasm; it is approximately 5 cm long and 
is divided into four portions: intraocular or optic disk (1 mm), intraorbital (25 mm), intracana-
licular within the optic canal (9 mm), and intracranial which terminates in the optic chiasm 
(12–16 mm) [3].
2.2. Optic chiasm
The optic chiasm measures approximately 12 mm wide, 8 mm long in the anteroposterior 
direction, and 4 mm thick. It is inclined at almost 45°, located just anterior to the hypothala-
mus and anterior to the third ventricle, and situated about 10 mm above the pituitary gland, 
which rests in the sella turcica of the sphenoid bone. The chiasm and sella are separated by a 
space called the suprasellar or inferior chiasmatic cistern [4].
As a result of variations in the length of the optic nerves, the exact location of the chiasm with 
respect to the sella is variable [4]. Most of the time, (80%) it is central and lies directly over the 
sella (expanding pituitary tumors involves chiasma first). In approximately 10% of individu-
als, it is prefixed as it lies more anteriorly over tuberculum sellae (pituitary tumors involves 
optic tract first), and in approximately 10%, it is posterior (postfixed) lying more posterior 
over dorsum sellae (pituitary tumors damage the optic nerve) [5–8].
The pituitary infundibulum, which arises from the hypothalamus (ventral diencephalon) 
behind the chiasm, extends downward to the posterior lobe of the pituitary (neurohypoph-
ysis). The anterior lobe of the pituitary (adenohypophysis) forms embryologically from 
Rathke’s pouch, an embryological structure connected to the pharynx. The chiasm is flanked 
laterally by the supraclinoid segments of the carotid arteries and inferolaterally by the cavern-
ous sinuses [8, 9].
At the optic chiasm, retinal ganglion cell axons from the temporal retina remain ipsilateral, 
and those from the nasal retina cross the chiasm and course toward the contralateral brain 
[10]. However, there are intricacies in the chiasmal crossing [11]. In the process of decussating, 
fibers from the inferior nasal quadrant loop forward into the opposite optic nerve for a short 
distance before turning back again, forming Wilbrand’s knee. In addition, some of the upper 
nasal fibers loop back briefly into the ipsilateral optic tract before decussation. In the chiasm, 
the fibers from the upper retinal quadrants lie superior, and those from the lower quadrants 
inferior. Inferior nasal fibers decussate anteriorly and inferiorly in the chiasm, while superior 
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nasal fibers cross posteriorly and superiorly. This accounts for the difference in the pattern of 
evolution of the field defect in infrachiasmatic versus suprachiasmatic lesions. Macular fibers 
more or less decussate as a group, forming a miniature chiasm within the chiasm, primarily 
in the posterior superior portion [11].
2.3. Visual field testing
The primary role of the clinician in the diagnosis of chiasmal disorders is to assess visual func-
tion accurately, interpret the results correctly, and, thus, localize the anatomical region that 
is affected. Visual field tests may provide a strong indication of direct chiasmal involvement, 
and failure to perform and properly interpret visual field tests is a common cause for delay in 
the diagnosis of chiasmal disorders [12].
Chiasmal injury is classically associated with bitemporal visual field defects due to damage 
to crossing fibers that carry temporal visual field information from the nasal retinas. Retinal 
ganglion cell axons from either side (right or left) of the macula travel together through the 
optic nerve but separate at the optic chiasm. This divergence creates the hemianopic midline 
and is the reason that all chiasmal and retrochiasmal visual field defects respect the vertical 
meridian [13].
Bitemporal defects that respect the vertical meridian indicate damage to the visual pathways 
at the optic chiasm [14]. It is important to establish that the vertical midline forms the border 
of the field depression and accordingly to rule out nonchiasmal temporal field loss that does 
not respect the vertical midline [12].
Bitemporal hemianopias may be complete (with no vision temporal to fixation in either eye), 
but when compression is early or mild, the hemianopia may be denser superiorly (when the chi-
asm is compressed from below) or inferiorly (when the chiasm is compressed from above) [13].
Because crossing macular fibers travel posteriorly, a lesion of the posterior chiasm may result 
in a central bitemporal hemianopia, sparing the more peripheral temporal fields [13].
Rarely, an anterior lesion at the junction of the optic nerve and the optic chiasm can injure 
crossing fibers from the opposite inferior retina (which loop forward into the optic nerve, 
forming Wilbrand’s knee, before projecting posteriorly to the optic tract). As a result, the optic 
nerve visual field defected in one eye may be accompanied by a superior temporal scotoma in 
the other eye: the junctional scotoma [13].
Lesions causing compression of the optic tract produce dissimilar incongruous homonymous 
defects in the hemifields contralateral to the affected optic tract [15].
3. Ophthalmologist’s role in pituitary tumors
Pituitary tumors are common benign tumors that represent about 12% of intracranial tumors [12].
Studies of several old series of pituitary tumors led to the old classical ophthalmology teaching 
that visual field abnormalities were an important early diagnostic sign of pituitary tumor [16].
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Henderson [17] reviewed Cushing’s series of 338 pituitary tumors in 1939. He found that 
chromophobe adenoma was almost never diagnosed before it had grown large enough to 
compress the anterior visual pathways causing field defects. Furthermore, he felt that no oper-
ation should be undertaken unless vision was at risk. In 1955, Chamlin et al. [18] reviewed 
156 cases of pituitary tumors and found that 86% of these cases had field defects. Hollenhorst 
et al. [19] analyzed 1000 cases of pituitary tumors, which were diagnosed between 1940 and 
1962, and found visual field defects in 70% of patients. Klauber et al. [20] reviewed 51 patients 
with pituitary tumors seen between 1967 and 1974 and reported a 69% incidence of field 
defects. Wray [21] examined 100 pituitary tumor patients between 1974 and 1976 and demon-
strated field defects in 31%. Anderson et al. [16] reported, in their study of 200 patients with 
pituitary tumors seen between 1976 and 1981, 9% incidence of field defects.
In comparing the above six studies done before 1981 and including all pituitary tumors 
regardless of their origin, size, and presenting symptoms, it was obvious that the incidence 
of ophthalmologic findings was decreasing in patients with pituitary tumors. This can be 
explained by the following several developments which enabled earlier diagnosis and treat-
ment before visual disturbance had occurred [16]:
1. Availability of prolactin assays: Prior to prolactin era, though the clinical syndromes of 
amenorrhea/galactorrhea in women had been described in pituitary tumors, their cause 
was not understood, as these tumors could be identified on plain skull x-rays, only in 
minority of patients when they were large enough to be seen. It is not surprising then 
that many of these patients received no specific therapy until they developed visual field 
defects.
2. Progress in radiologic imaging techniques: Prior to 1980, access to high-resolution CT 
scanning was limited, so this examination was carried out only in patients with large vis-
ual field defects. Since 1980 development of CT scanning techniques made it possible to 
visualize lesions smaller than 3 to 4 mm in diameter.
3. Development of surgical techniques: Before the development of selective transsphenoidal 
adenectomy techniques in which only the adenoma is removed and the rest of the pituitary 
is left intact, surgical removal of an adenoma was accomplished transfrontally by total 
hypophysectomy, with the resultant higher morbidity and mortality. Since the iatrogenic 
hypopituitarism was a major medical problem, surgical removal of pituitary adenomas 
was often not recommended until visual manifestations developed.
As a result of these developments, the ophthalmologist’s role in the diagnosis of pituitary 
tumors appeared to be changing from the classical teaching [16]. Patients became less likely 
to present primarily because of visual complaints but more likely to be referred to the oph-
thalmologist by an endocrinologist, gynecologist, or neurosurgeon during the course of a 
workup of a suspected pituitary tumor. However, for the small group of nonsecreting tumors, 
the ophthalmologist still has a primary role in that these patients will often present first with 
field defects.
Later on Poon et al. [22] performed a prospective study on 29 patients with visual deficits 
who presented to the neurosurgical unit for removal of pituitary macroadenomas between 
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1992 and 1994. All patients had visual field defects. It is noteworthy that out of the 29 patients, 
only 11 (37.9%) were referred by an ophthalmologist, which means that visual disturbance 
and visual field defects were the first presenting symptoms in only 37.9% of patients with 
macroadenomas. Other patients were referred by general practitioners, neurologists, endo-
crinologists, gynecologists, general physicians, and optometrists in 34.5, 10.3, 6.8, 3.4, 3.4, and 
3.4%, respectively.
Ren-Wen Ho et al. [1] reviewed retrospectively the records of 78 patients with pituitary ade-
nomas who were referred for transsphenoidal adenectomy between 2009 and 2011. Among 
these patients, 24 had small macroadenomas (>1 cm to ≤2 cm), 37 had large macroadenoma 
(>2 cm to ≤4 cm), and 17 had giant adenomas (>4 cm). Abnormal visual fields were found in 
65.4% of all patients. Patients with large macroadenomas and giant adenomas had a higher 
rate of abnormal visual field in comparison with patients with small macroadenomas (81.1, 
94.1, and 20.8%, respectively).
The increase in incidence of visual field defects in patients with pituitary tumors in reports 
published after the 1980s (varies from 65.4–100%) [1, 22] may be explained by the fact that 
recent studies were more specific and included in general only patients with macroadenomas, 
who were referred to neurologists for transsphenoidal adenectomy (these patients are more 
susceptible to have visual field defects), while reports before 1980s were more general and 
included all pituitary tumors regardless of their size, presenting symptoms, and indication 
for surgery.
Another way in which patients with pituitary tumors may present to the ophthalmologist 
is investigation of ocular causes of headache. Besides searching for primary ocular causes 
of headache, the ophthalmologist should be aware of performing careful visual fields in 
all headache patients. In addition to performing careful visual field examinations on rou-
tine headache patients, the ophthalmologist must be willing to question these patients about 
reproductive and sexual dysfunction and to refer these patients for appropriate neuroendo-
crine and neuroradiologic investigation [16].
4. Pituitary adenomas
Pituitary adenomas make up 12–15% of symptomatic intracranial neoplasms [12]. They are 
the most common causes of chiasmal compression and may occur at any adult age; they are 
rare in childhood [15].
Typically, nonfunctioning adenomas present as macroadenomas that cause neurological 
symptoms due to intracranial mass effects, since hormonal inactivity leads to a delay in 
diagnosis compared with functioning pituitary adenomas [23]. If pituitary adenomas are not 
treated, vision will continue to deteriorate and blindness might result [24].
A relationship exists between severity of visual impairment and tumor size [25]. Pituitary 
adenomas are usually classified into microadenomas, macroadenomas, and giant adenomas 
according to their size [26–29]. The larger the pituitary adenoma is, the higher is the risk of 
optic chiasm or optic nerve compression [16, 19, 30]. In general, the size of macroadenomas 
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range from 1 to 4 cm. Smaller macroadenomas typically will not result in any visual field 
defect or visual impairment, whereas the larger ones will usually cause severe visual disabil-
ity. Several studies clearly illustrated that patients with larger tumors tended to have visual 
field abnormality and that the severity of visual field defects was closely related to tumor size 
[31, 32]. Investigation of the relation between the severity of the visual impairment and the 
different sizes of macroadenomas by Ren-Wen Ho et al. [1] indicated that pituitary adenomas 
less than 2 cm usually have no or only a minimal effect on the visual pathway.
The typical visual field defect, bitemporal hemianopia, is due to the anatomical compression 
of the optic chiasm, which contains the crossing nasal fibers of each optic nerve. Nevertheless, 
the visual field defect actually depends on the relation between the optic chiasm and the 
tumor itself. If the tumor is anterior to the optic chiasm, or if the patient has an anatomical 
postfixed chiasm, conditions such as central scotoma, arcuate scotoma, and monocular visual 
constriction can be noted. If the tumor compresses the optic tracts, or the patient has a pre-
fixed chiasm, a homonymous hemianopia might be seen [31, 33, 34].
Ren-Wen Ho et al. [1] found that large macroadenomas and giant adenomas leading to visual 
impairment are mostly nonfunctioning adenomas (97.8%). This result is consistent with other 
reports [16, 35] and can be explained by the absence of endocrine symptoms, which often 
result in a delay of the diagnosis since there are no early visual symptoms [16]. This explana-
tion is consistent with what Monteiro et al. [32] have mentioned previously that nonfunction-
ing and prolactin-secreting adenomas are the most likely pituitary tumors associated with 
visual impairment.
In general, larger volume tumors will usually result in a higher risk of compression at the 
optic chiasm; however, this relationship is not found when tumor extension mainly occurs at 
the infrasellar or parasellar region instead of the suprasellar region. It was found that if the 
adenoma grows in the vertical direction, it will usually result in more severe visual impair-
ment. If the adenoma grows in the horizontal direction, it will usually cause less vision dam-
age. Horizontal growth of the adenoma may invade the cavernous sinus [1].
Furthermore, some studies have already discussed the relationship between the optic chiasm 
position and visual loss. Ikeda and Yoshimoto [36] found that visual impairment occurred 
when the displacement of the optic chiasm was more than 8 mm above the reference line on 
the sagittal image and more than 13 mm above on the coronal image on brain MRI. Monteiro 
et al. [32] have also shown that tumor exceeding 10 mm above the sagittal standard line and 
12 mm above the coronal standard line had a significant effect on visual loss. Ren-Wen Ho 
et al. [1] found that significant visual impairment occurred when the optic chiasm was moved 
by the tumor more than 11.2 mm above the reference line on the sagittal view and more than 
15.3 mm on the coronal image.
With regard to visual improvement after surgery for pituitary adenoma, Ren-Wen Ho et al. [1] 
reported visual improvement in 88.7% with complete recovery of vision in 27.67% of patients. 
They found that patients with large macroadenomas or giant adenomas experienced greater 
visual improvement after surgical resection compared with patients who had micro- or small 
macroadenomas, but patients with smaller pituitary adenomas still had a better visual out-
come. Other series have reported that visual improvement depends on the surgical approach, 
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ranging from 74.7 to 93.4% [24, 37, 38]. Gnanalingham et al. [35] believed that better preopera-
tive visual acuity and a smaller degree of impairment in preoperative visual field would have 
a better effect on the visual outcome.
There have been contradictory results regarding predictive factors for recovery of vision. 
Müslüman et al. [24] found that tumor size was not significantly associated with the postop-
erative visual impairment score, but preoperative visual deficit and the time interval between 
the initial visual symptom and surgery were the factors significantly associated with the post-
operative visual impairment score. A shorter duration of symptoms, younger age, and a bet-
ter preoperative best-corrected visual acuity (BCVA) have been reported to be associated with 
better postoperative recovery of visual field by some investigators [35].
Undoubtedly, vision can rapidly improve within minutes or days after tumor resection [39]. 
Among all surgical resection procedures, transsphenoidal adenectomy is likely most effective 
for providing rapid relief of visual symptoms in patients with a pituitary adenoma [40, 41]. 
Thus, early surgical resection of the tumor should be considered for patients with a large or 
giant macroadenoma causing visual loss, in order to preserve their vision.
5. Pituitary apoplexy
Pituitary apoplexy is the sudden enlargement of a pituitary gland, as a result from hemor-
rhage or infarction (most commonly hemorrhagic infarction) of a pituitary adenoma [42]. 
Pituitary apoplexy is typically associated with acute headache, visual field or vision loss, oph-
thalmoplegia, facial pain, or facial numbness.
Sudden expansion of the tumor into the adjacent cavernous sinuses can cause dysfunction 
of cranial nerves III, IV, V, and VI, with cranial nerve III as the most commonly affected one. 
Superior extension causes visual field loss; it also may cause central visual loss up to no light 
perception vision. Extravasation of blood into the subarachnoid space causes numerous symp-
toms, including a decreased level of consciousness and vasospasm with secondary stroke. The 
acute endocrine abnormalities may lead to numerous complications, including adrenal crisis. 
Therefore, recognition of pituitary apoplexy is crucial, as treatment is initiated emergently. 
Treatment includes immediate administration of corticosteroids, surgical decompression of 
the sella, and appropriate supportive measures. Some authorities recommend conservative 
management when neuro-ophthalmic signs are absent or mild [15].
The normal pituitary gland also may undergo hemorrhagic or nonhemorrhagic infarction, 
but such episodes generally do not cause visual loss and may go unrecognized until hypo-
pituitarism develops. Predisposing factors include pregnancy, estrogen therapy, obstetrical 
hemorrhage (Sheehan’s syndrome), diabetes mellitus, bleeding disorders, long-term antico-
agulation, blood dyscrasias, radiation therapy, trauma, angiography, atheromatous emboli, 
cardiac surgery, coughing, positive pressure ventilation, and vasoactive agents [12].
As presentation of acute pituitary apoplexy is variable and its course is unpredictable, it should 
be considered in any patient with abrupt neuro-ophthalmological deterioration associated with 
headache. Although early investigators suggested that pituitary apoplexy occurs primarily 
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in patients with large macroadenomas, it is now evident that tumors of almost any size may 
undergo hemorrhagic necrosis [43, 44].
6. Lymphocytic adenohypophysitis
Lymphocytic adenohypophysitis is an immune-mediated diffuse lymphocytic infiltration 
of the pituitary gland; it has been reported to cause chiasmal compression from suprasellar 
extension [45]. This uncommon condition was reported in women only, and over one-half of 
the cases was found to occur during the perinatal period.
7. Craniopharyngioma
Craniopharyngiomas comprise 3% of all intracranial tumors, 13% of intracranial neoplasms 
in childhood, and 30% of all new growths in the hypophyseal area [46]. Since ocular signs are 
frequently the presenting features of these tumors, it is clear that their recognition by oph-
thalmologist is of great importance for establishing early diagnosis and treatment and more 
favorable prognosis.
Craniopharyngioma is a benign tumor, of ectodermal origin, arising from squamous cell rem-
nants of Rathke’s pouch. These cell remnants occur mainly on the infundibulum, between the 
undersurface of the brain and the upper surface of the pituitary gland [46]. The tumor may be 
entirely suprasellar or partially intrasellar, resulting in avascular solid tissue mass in which 
calcification may occur, as well as cysts filled with cellular debris and cholesterol crystals 
[46]. About 90% of tumors contain cysts, some of which may be very large [47]. These tumors 
may produce variable symptoms and signs depending on their size, direction of growth, 
and degree of compression of the optic pathways, pituitary area, hypothalamus, and third 
ventricle.
One of the striking features in craniopharyngioma is the variation in visual acuity and visual 
field loss, observed with disease progression [46]. Thus, information should be gathered from 
repeated field testing rather than from any single measurement [46]. These fluctuations can 
occur in both solid tumors (perhaps due to local edema) and in cystic variety (from intermit-
tent emptying of the cyst into the ventricles) [48].
Kennedy and Smith [46] found in their study of 45 patients with craniopharyngioma that the 
majority of adults presented with visual failure and optic atrophy. Bitemporal hemianopia 
was fairly frequent (found in 27% of patients at the time of diagnosis) but was asymmetrical 
and unpredictable in its evolution. Homonymous hemianopia was relatively common (found 
as presenting feature in 11% of patients). Full fields were found initially in 20% of patients, a 
high incidence compared with pituitary adenomas or suprasellar meningiomas. Furthermore, 
Kennedy and Smith [46] detected pleomorphism (a distinct change from one type of field 
defect to another, with progress of the disease), which is a characteristic feature of the tumor 
(as indeed are fluctuations in the clinical state and visual acuity), in 22% of their patients.
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In children, there are two main presenting syndromes [48]: (1) symptoms and signs of raised 
intracranial pressure, resulting from obstruction of the third ventricle by the tumor, and (2) 
visual failure from compression of the visual pathways. Kennedy and Smith [46] pointed out 
that, in those patients who have raised intracranial pressure, optic atrophy may be found 
rather than papilledema.
In addition, strabismus is a common finding in craniopharyngioma patients, and it can be 
classified into three categories [46, 49]:
1. Cases of concomitant esotropia or exotropia following marked loss of central vision in one 
or both eyes:
Kennedy and Smith [46] reported this type of squint as an early feature of craniopharyngioma in 
30% of children included in their study. As the presence of optic atrophy or sluggish pupil may 
be missed in a young child, the poor vision in the squinting eye may be wrongly attributed to 
strabismic amblyopia until it is realized that the visual acuity is deteriorating despite treatment.
2. Cases of paralytic strabismus:
The incidence of paralytic strabismus was variable between different case series of cranio-
pharyngioma. Love and Marshall [49] found in year 1950 third nerve palsy in 10% of their 
cases, while Hoff and Patterson reported in 1972 the incidence of cranial nerve palsies in 25% 
of children and 33% of adults [46]. Wybar found in 1971 two cases of third nerve palsy and 
one case of sixth nerve palsy, in 72 cases [46]. Kennedy and Smith [46] had only one patient 
in their series with transient sixth nerve paresis and were surprised not to have more cases 
of ophthalmoplegia, in spite of the massive size of the cystic tumor present in many of their 
craniopharyngioma patients.
3. Cases of non-paretic diplopia:
It is characterized by episodes of diplopia in the absence of demonstrable ocular palsy or defect 
of ocular movement [46], which was attributed to disturbance of binocular vision, secondary to 
bitemporal hemianopia and reduction of the area of visual field overlap common to the two eyes.
Endocrine disorders are also common in craniopharyngioma especially in adults, and mental 
deterioration is a frequent presenting feature in patients over 30 years of age [46]. Straight 
x-rays of the skull are practically diagnostic of craniopharyngioma in children, but in adults a 
normal x-ray does not exclude the diagnosis.
8. Sellar and suprasellar meningiomas
Meningiomas in the region of the sella turcica are rare, representing about 1% of all sellar 
masses [50]. They typically originate and involve the suprasellar region but in unusual cases 
arise from within the sella. Sellar/suprasellar meningiomas can mimic both clinically and 
radiologically, any of the other nonhormone-secreting sellar region masses, in particular the 
nonfunctioning pituitary adenomas. They can cause loss of visual acuity, visual field distur-
bances, hypopituitarism, hyperprolactinemia, or a combination of the above [51].
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Kwancharoen et al. [52] analyzed a retrospective series of subset of 44 patients with sellar/
suprasellar meningiomas and adequate MRI imaging study, who underwent surgery at the 
Johns Hopkins Hospital during a 12-year period (between 2000 and 2012). They were mostly 
diagnosed in the sixth decade (age ranges between 30 and 78 years). The female/male ratio 
was 6:1, quite higher than the reported one in the previous series and higher than the ratio 
found in the entire meningioma cohort (2.7:1) [53–55]. The most common presenting symp-
toms were visual disturbance (85.96%), although some series report them in an even higher 
proportion (82.4–100%) [53, 54], and this was followed by headaches (49.12%), diplopia 
(12.28%), and ptosis (7.02%). A small proportion of patients had symptoms of endocrine dys-
function. Among these, hyperprolactinemia was the most common one, highlighting the fact 
that prolactin can be above the threshold in nonprolactin-secreting sellar masses. An addi-
tional meningioma was found in two cases (3.5%), one in the region of the falx cerebri and one 
in the middle cranial fossa [52].
MRI is the investigation of choice in these cases because it can often show the dural origin of the 
tumor [52]. In agreement with the previous series [56, 57], most of the tumors (81.25%) reported 
by Kwancharoen et al. [52] were iso-intense in T1. On T2-weighted imaging, the tumors were 
hyperintense in 35%, iso-intense in 30%, and hypointense in 25% of the cases [52].
Due to the high vascularity, gadolinium enhancement of meningiomas is usually marked, 
homogeneous, and rapid [58, 59]. This enhancement pattern may be helpful in distinguish-
ing them from adenomas. However, in Kwancharoen et al.’s sellar/suprasellar series [52] in 
almost 11% of cases, the mass was thought to be a pituitary adenoma. This fact points out 
the significant challenges of establishing the diagnosis through radiology alone and necessi-
tates further work to establish more accurate clinical and radiologic means of distinguishing 
between meningiomas and macroadenomas in the region of the sella turcica.
Because of the fibrous content in histology and expression of angiogenesis factors, meningio-
mas are usually adhesive, firm, and high vascular and may have major intraoperative bleed-
ing and worse surgical outcome when compared to pituitary adenomas [60].
Previous series report worsening of vision in approximately 20–30% after surgery for sel-
lar and parasellar meningiomas [53, 61–63]. Kwancharoen et al. [52] found deterioration of 
vision in 10.5% of cases after surgery (79.6% had improvement of one or more symptoms, 
improvement of vision occurred in 79.6%, and improvement of headache in 7.14%). It was 
proposed that surgical techniques might affect this outcome, as optic nerve manipulation and 
devascularization of perforating arteries supplying the optic apparatus are important factors 
for visual outcome [63, 64]. As Kwancharoen et al. [52] reported outcomes of more recent 
surgeries, the lower prevalence of vision deterioration when compared with previous reports 
might reflect the historical improvement in surgical techniques.
9. Parasellar meningiomas
Parasellar meningiomas occur most often in middle-aged women; arise most frequently from 
the tuberculum sella, planum sphenoidale, or anterior clinoid; and often produce asymmetric 
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bitemporal vision loss. Parasellar meningiomas may also enlarge and produce chiasmal com-
pression during pregnancy [15].
Parasellar involvement manifests with abnormalities of ocular motility, pupillary function, 
or facial sensation from injury to cranial nerves III, IV, V1, V2, or VI or the ocular sympa-
thetic nerves in the parasellar region [12]. Injury to these structures within the cavernous 
sinus may be associated with complaints of diplopia, ptosis, unequal pupil size, accommoda-
tive difficulty, facial pain or numbness, or eye pain. Signs include ocular motor nerve palsies, 
decreased sensation in the areas innervated by the first and second divisions of the trigeminal 
nerve, or Horner’s syndrome [12]. Multiple cranial nerve involvement is more suggestive of 
invasive malignant tumors [12].
Therapy of parasellar tumors is complex and depends on the age of the patient; the nature, 
location, and extent of the tumor; its hormonal activity; and the severity of symptoms [15].
The ophthalmologist’s role in the management of parasellar tumors is crucial, in that the first 
sign of recurrence may be vision loss [15]. Baseline visual field and visual acuity testing should 
be performed 2–3 months after treatment and at intervals of 6–12 months thereafter, depend-
ing on the course. Visual acuity and visual fields should be rechecked more often (immediately 
if necessary) if the patient notes any ongoing change. Periodic neuroimaging is essential [15].
Delayed vision loss after therapy for parasellar lesions should prompt the following consid-
erations [15]:
• Tumor recurrence.
• Delayed radio necrosis of the chiasm or optic nerves.
• Chiasmal distortion due to adhesions or secondary empty sella syndrome, with traction 
on the chiasm.
• Chiasmal compression from expansion of intraoperative over packing of the sella with fat.
Neuroimaging effectively helps differentiate among these entities and guides further man-
agement decisions [15].
10. Conclusion
Due to developments in laboratory assays, radiological imaging, and surgical techniques, 
patients with pituitary tumors became less likely to present primarily to the ophthalmologist 
because of visual complaints. These patients are more likely referred to ophthalmologists by 
the endocrinologist, gynecologist, or neurosurgeon at earlier stages of pituitary disease dur-
ing the course of workup. However, the ophthalmologist still has a primary role in patients 
with nonsecreting tumors, where patients will present first with visual and field defects. 
Patients with pituitary apoplexy usually present with acute headache, visual field or vision 
loss, ophthalmoplegia, facial pain, or facial numbness. In craniopharyngioma, strabismus is 
a common finding. It can be concomitant or paralytic. In addition, the patient may complain 
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of non-paretic diplopia. The most common presenting sign in sellar/suprasellar meningiomas 
is visual disturbance, followed by headaches, diplopia, and ptosis. Parasellar meningiomas 
manifest with ocular motility abnormalities, abnormal pupillary reaction, as well as abnormal 
facial sensation; these complaints result from injury to cranial nerves III, IV, V1, V2, or VI and 
ocular sympathetic nerves in the parasellar region.
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